查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863341

下一代體外診斷市場按產品類型、技術、最終用戶、應用、測試類型和檢體類型分類－2025年至2032年全球預測

Next-Generation IVD Market by Product Type, Technology, End User, Application, Test Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，下一代體外診斷市場將成長至 1,002 億美元，複合年成長率為 5.43%。

關鍵市場統計數據
基準年 2024 656億美元
預計年份：2025年 692.4億美元
預測年份 2032 1002億美元
複合年成長率 (%) 5.43%

技術融合、不斷變化的法規和變革性的醫療保健服務這三大力量正在推動診斷策略的根本性轉變，重塑產業相關人員。

體外診斷業界正處於快速技術創新、醫療服務模式變革以及對診斷速度、準確性和數據整合日益成長的需求交匯點。臨床相關人員不僅需要能夠提供準確結果的診斷解決方案，還需要這些方案能夠無縫整合到診療流程中，支援分散式檢查，並實現人群層面的監測。分子診斷技術的成熟、數位健康工具的普及以及就地檢驗的擴展，正迫使各機構重新評估其產品藍圖、夥伴關係和供應鏈策略，以保持競爭力。

法規結構和支付方的期望都在同步演變，更加強調臨床效用、真實世界數據和互通性。這些變化迫使製造商加大對檢驗研究、品管和上市後資料收集的投入。此外，醫療機構和實驗室正在調整服務模式，以平衡集中式高通量檢測和床邊診斷，這需要靈活的設備、耗材策略和維護模式。

在此背景下，競爭優勢日益取決於能否將強大的分析效能與精簡的工作流程、靈活的軟體以及能夠降低整體擁有成本的服務相結合。能夠有效將新興科學轉化為臨床相關且易於部署的解決方案的公司，將在診斷實驗室、醫院和診所網路、照護現場以及研究機構中獲得更大的影響力。本分析引言概述了影響因素，並為深入探討變革性轉變、貿易政策的影響、市場區隔洞察以及區域性考量奠定了基礎。

識別能夠顛覆傳統診斷模式、開闢臨床影響和商業性差異化新途徑的關鍵技術和營運變革。

技術融合、新的臨床重點以及對可操作數據的關注正在推動多項變革性轉變，從根本上改變體外診斷的發展軌跡。首先，分子診斷已從專業實驗室走向常規臨床應用，聚合酵素鏈鎖反應平台和等溫擴增技術能夠快速且靈敏地檢測傳染性病原體和基因標記。這項轉變引發了檢測化學和試劑設計的革新，重點在於提高在分佈式環境下的穩定性。

其次，數位化整合和資料管理已成為核心差異化因素。將設備輸出與實驗室資訊系統、雲端基礎分析工具和決策支援工具連接起來，能夠實現患者長期追蹤、人群監測和人工智慧輔助解讀，進而提升診斷價值。互通性標準和網路安全措施已成為軟體供應商和設備製造商的核心設計要求。

第三，就地檢驗的普及反映了醫療服務模式的轉變，強調在門診、急診和社區醫療機構進行快速診斷。這一趨勢正在重塑產品設計，使其更加重視便攜性、簡化的工作流程和低維護成本。同時，服務模式也在不斷發展，包括基於結果的維護、遠距離診斷和基於訂閱的試劑供應，從而使醫療服務提供者和供應商之間的獎勵更加一致。

最後，監管和報銷環境也在不斷調整，以適應創新檢測和數位診斷技術，這要求製造商不僅要提供分析檢驗，還要提供真實世界證據。這些變化需要一種整體性的商業性策略，在創新與供應鏈、生產擴充性和上市後支援等實際因素之間取得平衡。

分析近期美國關稅如何重塑診斷設備和試劑整個生命週期的採購、定價結構和供應鏈韌性。

2025年美國關稅的累積影響正對診斷價值鏈的各個環節施加多方面的壓力，促使企業重新評估採購、定價和在地化策略。關鍵儀器組件、試劑原料和成品的關稅加劇了投入成本的波動，並增加了製造商和實驗室的採購複雜性。為此，許多公司正在審查其供應商網路，以減少對關稅風險地區的依賴，並加快製造地的多元化。

除了直接的成本影響外，關稅也在影響醫療設備的採購行為。醫療機構在考慮購買醫療設備時，現在會考慮長期總成本，包括潛在的進口關稅、物流前置作業時間和維護零件的供應情況。這促使人們更加關注國產設備以及關鍵零件來自免稅地區的設備。此外，人們也越來越重視能夠保證零件和試劑穩定供應的服務契約，以抵消關稅造成的價格波動。

從策略角度來看，關稅正促使企業重新關注供應鏈韌性和垂直整合。各公司正在探索關鍵試劑的國內生產和本地組裝，以穩定交貨時間並保持競爭力。同時，區域監管和貿易政策的變化也帶來了行政上的複雜性，要求製造商遵循不同的合規途徑並提交不同的文件，以獲得關稅豁免和優惠待遇。

綜合來看，2025 年的關稅環境已經將決策從短期採購授予轉向長期供應鏈重組、供應商夥伴關係以及強調模組化、本地支援和可預測的生命週期經濟效益的產品策略。

分析包括產品、技術、最終用戶、應用、檢體類型和樣本類型在內的多維度細分，以確定目標商業化需求和臨床優先事項。

透過詳細的市場區隔方法，可以揭示不同產品類型、技術、最終用戶、應用、檢體類型和樣本類型所帶來的差異化需求、採用模式和商業化路徑。按產品類型分類，市場格局包括化學分析儀、免疫檢測和PCR儀等儀器；涵蓋臨床化學試劑、免疫檢測儀和分子診斷劑的試劑和試劑套件；以及數據管理平台和維護服務等軟體和服務。每種產品類型都需要不同的市場推廣模式：儀器主要依靠資本支出銷售，試劑主要依靠重複消費和供應鏈最佳化，而軟體和服務則主要依靠整合和生命週期收入。

技術細分突顯了底層技術的多樣性，包括依賴電化學或光強度檢測的臨床化學平台；採用化學發光免疫分析 (CLIA)、酶聯免疫吸附試驗 (ELISA) 和流動注射分析 (FIA) 等形式的免疫檢測系統；從基於培養的方法到分子檢測的各種微生物學方法；以及包括等溫增、基於 PCR 的工作流程和基於 PCR 的工作流程在內的結果的解決方案。技術選擇會影響檢測週轉時間、靈敏度、基礎設施需求和實驗室人員配備模式，進而影響各種臨床環境中的部署模式。

終端使用者細分涵蓋診斷實驗室（包括醫院實驗室和參考實驗室）、醫院和診所（包括二級和三級醫院）、照護現場機構以及研究機構。不同終端使用者的採用趨勢各不相同：高通量實驗室優先考慮自動化和高通量，醫院強調整合工作流程和照護現場能力，而研究機構則專注於靈活性和新型檢測方法的實施。應用層級的差異包括自體免疫疾病檢測（例如乳糜瀉、狼瘡和類風濕性關節炎） ；心臟病學檢測（例如心臟標記和血脂譜）；傳染病檢查檢測（例如 COVID-19、肝炎、HIV 和結核病）；神經病學診斷（例如阿茲海默症和帕金森氏症）；以及每種腫瘤學檢測（包括血液學和固態腫瘤檢測），每種腫瘤學檢測的

檢測類型（定性、定量、半定量）以及檢體類型（血液、唾液、組織、尿液等）的差異會影響檢測設計、監管分類和使用者培訓要求。這種多方面的細分凸顯了製定客製化商業策略的必要性，這些策略應使產品開發、監管規劃、報銷談判和客戶支援與每個細分市場的具體需求保持一致。

檢驗美洲、歐洲、中東和非洲以及亞太地區的區域市場動態如何影響產品採用、製造策略和市場進入途徑。

區域趨勢正在以不同的方式塑造美洲、歐洲、中東和非洲以及亞太地區的需求、創新中心和投資模式。在美洲，成熟的實驗室網路和先進的報銷系統持續推動對整合自動化、分子平台和資料管理解決方案的需求，而大型醫院系統和參考實驗室則需要可擴展的工作流程和檢驗的數位化整合。策略夥伴關係和在地化服務交付對於滿足客戶對快速安裝、認證維護和持續試劑供應的期望變得日益重要。

在歐洲、中東和非洲地區，多樣化的監管要求和醫療保健資金籌措模式既帶來了複雜性，也帶來了機會。該地區分散的市場結構有利於那些能夠駕馭各種合格評估途徑、證明其產品在多個醫療保健系統中具有臨床效用並提供靈活商業模式的製造商。此外，對公共衛生基礎設施和感染疾病監測的投資也推動了對分散式檢查和強大的實驗室參考檢測能力的需求。

亞太地區既有成熟市場，也有新興市場。分子診斷技術的快速普及、對就地檢驗的濃厚興趣以及豐富的本地生產能力，正推動著日益激烈的市場競爭。區域供應鏈生態系統，包括組件供應商和試劑生產商，能夠實現產品的快速本地化；而不同的臨床實踐模式和監管重點，則需要量身定做證據生成和市場進入策略。在所有地區，永續性考量、勞動力供應和數位基礎設施都將繼續影響部署時間表和客戶預期。

了解製造商、軟體供應商和服務供應商如何調整其產品組合、夥伴關係和供應鏈，以確保在診斷領域獲得競爭優勢。

為了抓住不斷成長的診斷市場機遇，產業領導者正積極尋求平台整合、策略合作以及以服務為中心的模式相結合的解決方案。製造商正投資於模組化儀器架構，以支援更廣泛的檢測項目，同時加快新檢測產品的上市速度。此外，對試劑穩定性、標準化耗材介面和遠距離診斷功能的配套投資，也透過提升運轉率和整體成本透明度，增強了客戶維繫。

軟體和數據管理供應商正逐漸成為關鍵的合作夥伴，他們提供互通性層、雲端分析和決策支援工具，以提升實驗室產出的臨床效用。這些供應商也與儀器製造商簽訂共同開發契約，提供承包解決方案，簡化醫療機構的採購和整合流程。同時，服務機構也在拓展維護、培訓和試劑生命週期管理項目，以使商業性獎勵與實驗室績效指標保持一致。

策略性併購活動和聯盟的建立將進一步影響競爭差異化，其目的在於彌合檢測組合、地理覆蓋範圍和數位化能力方面的差距。能夠展現可靠證據包、高效監管流程和健全上市後監測能力的公司，將在贏得與醫療系統和大型參考實驗室的長期合約方面更具優勢。卓越的供應鏈，包括多元化採購、在地化生產和敏捷物流，將繼續成為商業性韌性和客戶信任的關鍵因素。

為產業領導者提供可操作的策略重點，以協調產品架構、資料整合、證據產生和彈性供應鏈，加速產品普及。

為了在新一代診斷時代取得成功，產業領導者應優先考慮產品開發、供應鏈韌性、證據產生和市場推廣策略的整合方法。首先，投資於模組化儀器設計和開放式耗材系統能夠快速擴展檢測範圍，並減少對單一來源組件的依賴，從而能夠快速回應臨床需求和關稅相關的供應中斷。這種架構靈活性有助於與各種軟體生態系統整合，並支援集中式和分散式環境中的混合部署模式。

接下來，透過將可互通的數據管理功能融入核心產品，強化您的數據策略。這包括採用行業數據標準、確保強大的網路安全，以及開發能夠將實驗室結果轉化為可操作臨床見解的分析技術。向支付方和醫療服務提供者展示資料整合如何改善臨床路徑和營運效率，對於獲得他們的認可至關重要。

第三，我們制定了一套證據產生藍圖，該路線圖超越了分析檢驗，涵蓋了真實世界績效評估、健康經濟學評估和結果研究，以支持醫保報銷和臨床指南納入。我們與關鍵意見領袖、臨床網路和參考實驗室合作，產生符合監管機構和支付方期望的可重複的多中心數據。

最後，我們將積極重塑供應鏈和商業模式，以降低關稅風險，包括將關鍵製造流程外包、實現供應商多元化，以及提供靈活的商業條款，例如試劑即服務和全面的維護合約。我們將優先採用以客戶為中心的服務模式，強調運轉率、培訓和本地技術支持，以建立持久的客戶關係並推動產品的長期應用。

我們解釋了支撐這項分析的透明的、以訪談主導的、證據三角驗證的調查方法，以確保可複製性和戰略相關性。

本研究採用綜合分析調查方法，旨在為策略決策提供堅實透明的基礎。主要資料來源包括對臨床實驗室主任、醫院採購主管、診斷研發主管和支付方進行結構化訪談，以收集關於技術需求、應用障礙和報銷優先事項的第一線觀點。這些定性見解與監管文件、同行評審文獻、臨床指南和行業公告等二手資料進行三角驗證，以檢驗技術和商業趨勢。

此分析方法利用交叉細分映射來評估產品類型、技術、最終用戶、應用領域、測試類型和檢體矩陣如何相互作用，從而影響產品採納路徑和商業化策略。此調查方法強調可重複性，透過記錄資料來源、訪談程序和分析假設來實現，並對與供應鏈中斷和政策變化相關的測試場景進行敏感度分析。

倫理考量和資料管治是研究途徑不可或缺的一部分。用於二次分析的病患層級資料均已匿名化，透過訪談所獲得的專有資訊也已匿名化，除非獲得明確的署名許可。最終的綜合分析旨在提供符合臨床、監管和商業領域利益相關人員實際情況的、可信、透明且可操作的見解。

本文探討了技術整合、實證策略和供應鏈韌性將如何決定診斷產業的未來競爭優勢。

體外診斷領域的格局正因技術創新、不斷演進的醫療服務模式和不斷變化的政策趨勢而重塑。能夠成功駕馭這一格局的機構，將整合模組化產品設計、強大的數據策略和穩健的供應鏈，同時投資於必要的真實世界證據，以滿足監管機構和醫保報銷相關人員的需求。儀器、試劑和軟體之間的相互作用不斷創造捆綁銷售的機會，從而簡化採購流程並提升臨床效用。

區域差異和關稅相關的供應鏈因素增加了商業性複雜性，但也為能夠實現本地化生產、提供以服務為中心的商業模式並展現清晰的臨床和經濟價值的製造商創造了機會。包括實驗室、醫院/診所、照護現場機構和研究機構在內的終端用戶，將尋求能夠提供可預測的性能、無縫整合和課責的服務模式的合作夥伴。

總之，診斷領域的下一個競爭優勢將屬於那些能夠將技術能力轉化為可部署解決方案，並使其與臨床工作流程、支付方要求和實際營運情況相符的機構。對模組化平台、互通軟體、在地化生產和實證醫學的策略性投資，將為相關人員應對新興臨床需求並在診斷生態系統中實現永續發展奠定基礎。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合人工智慧和機器學習演算法以提高照護現場診斷的敏感度和特異性
  • 開發一種連接複用微流體平台，用於同時檢測單一患者檢體中的多種生物標記
  • 在體外診斷設備中採用數位健康連接技術，實現即時遠端監測和數據分析整合
  • 基於 CRISPR 的基因編輯技術在臨床檢體中超快速、高特異性檢測致病核酸方面取得進展
  • 在新一代免疫檢測中，新型奈米材料（如量子點和金奈米粒子）在訊號放大的應用日益廣泛
  • 利用智慧型手機感應器擴展分散式居家傳染病篩檢分散式檢查模式
  • 個人化醫療舉措的成長推動了對標靶治療伴隨診斷測試的需求。
  • 監管政策轉變，強調對創新體外診斷技術制定嚴格的檢驗標準和快速核准流程。
  • 人們越來越關注永續的、一次性體外診斷試劑盒設計，以最大限度地減少生物危害廢棄物和環境影響。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按產品類型分類的下一代體外診斷市場

  • 裝置
    • 化學分析儀
    • 免疫檢測裝置
    • PCR裝置
  • 試劑和套件
    • 臨床化學試劑
    • 免疫檢測試劑
    • 分子診斷劑
  • 軟體和服務
    • 資料管理軟體
    • 維護服務

第9章：按技術分類的下一代體外診斷市場

  • 臨床化學
    • 電化學
    • 比色法
  • 免疫檢測
    • CLIA
    • ELISA
    • FIA
  • 微生物學
    • 文化基礎
    • 分子
  • 分子診斷
    • 等溫擴增
    • 基於PCR的
    • 定序定序

第10章：按最終用戶分類的下一代體外診斷市場

  • 診斷實驗室
    • 醫院檢查室
    • 參考實驗室
  • 醫院和診所
    • 二級護理醫院
    • 三級醫療中心
  • 照護端
  • 研究所

第11章 依應用分類的下一代體外診斷市場

  • 自體免疫疾病
    • 乳糜瀉
    • 狼瘡
    • 類風濕性關節炎
  • 心臟病學
    • 心臟標記物
    • 脂質
  • 感染疾病
    • 新型冠狀病毒感染疾病（COVID-19）
    • 肝炎
    • HIV
    • 結核
  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 血液學
    • 固態腫瘤

第12章：下一代體外診斷市場（依檢測類型分類）

  • 定性
  • 定量
  • 半定量

第13章：依檢體類型分類的下一代體外診斷市場

  • 血
  • 唾液
  • 組織
  • 尿

第14章：按地區分類的下一代體外診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：按組別分類的下一代體外診斷市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國下一代體外診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Sysmex Corporation
    • QIAGEN NV
    • Mindray Medical International Limited
Product Code: MRR-2E76C3E47F6A

The Next-Generation IVD Market is projected to grow by USD 100.20 billion at a CAGR of 5.43% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 65.60 billion
Estimated Year [2025] USD 69.24 billion
Forecast Year [2032] USD 100.20 billion
CAGR (%) 5.43%

Framing the urgent transformation in diagnostic strategy as technological convergence, regulatory evolution, and care delivery shifts redefine success for industry stakeholders

The current moment for in vitro diagnostics is defined by a rapid intersection of technological innovation, shifting care delivery models, and increasing demands for diagnostic speed, precision, and data integration. Clinical stakeholders are seeking diagnostic solutions that not only return accurate results but also integrate seamlessly into care pathways, support decentralized testing, and enable population-level surveillance. As molecular methods mature, digital health tools gain traction, and point-of-care modalities proliferate, organizations must reassess product roadmaps, partnerships, and supply chain strategies to remain relevant.

Regulatory frameworks and payer expectations are concurrently evolving, emphasizing clinical utility, real-world evidence, and interoperability. These changes are prompting manufacturers to invest more heavily in validation studies, quality management, and post-market data collection. Moreover, providers and laboratories are reconfiguring service delivery to balance centralized high-throughput testing with near-patient diagnostics, requiring flexible instrumentation, consumables strategies, and maintenance models.

Against this backdrop, competitive differentiation is increasingly driven by the ability to combine robust analytical performance with streamlined workflow, adaptable software, and service offerings that reduce total cost of ownership. Companies that effectively translate emerging science into clinically meaningful, easy-to-deploy solutions will capture influence across diagnostic laboratories, hospitals and clinic networks, point-of-care environments, and research institutions. The introduction to this analysis frames the core forces at play and sets the stage for deeper discussion of transformative shifts, trade policy impacts, segmentation insights, and regional considerations.

Identifying the pivotal technological and operational shifts that are disrupting traditional diagnostic models and creating new avenues for clinical impact and commercial differentiation

Several transformative shifts are fundamentally changing the trajectory of in vitro diagnostics, driven by technological convergence, new clinical priorities, and an emphasis on actionable data. First, molecular diagnostics have moved from specialized laboratories toward more routine clinical use, with polymerase chain reaction platforms and isothermal amplification technologies enabling faster, sensitive detection of infectious agents and genetic markers. This shift is accompanied by a renaissance in assay chemistry and reagent design that prioritizes robustness across decentralized settings.

Second, digital integration and data management have become core differentiators. The ability to harmonize instrument outputs with laboratory information systems, cloud-based analytics, and decision-support tools enhances diagnostic value by enabling longitudinal patient tracking, population surveillance, and AI-assisted interpretation. Interoperability standards and cybersecurity considerations are now central design criteria for both software vendors and instrument manufacturers.

Third, the expansion of point-of-care testing reflects changing care delivery models that emphasize rapid diagnosis in outpatient clinics, emergency departments, and community settings. This trend is reshaping product engineering to focus on portability, simplified workflows, and low-maintenance operation. Concurrently, service models are evolving to include outcome-linked maintenance, remote diagnostics, and subscription-based reagent supply that align incentives across providers and vendors.

Finally, regulatory and reimbursement landscapes are adapting to accommodate innovative assays and digital diagnostics, driving manufacturers to generate not only analytical validation but also real-world clinical evidence. Together, these shifts demand an integrated commercial approach that balances innovation with pragmatic considerations around supply chains, manufacturing scalability, and post-market support.

Analyzing how recent United States tariff measures have reshaped sourcing, pricing structures, and supply chain resilience across the diagnostic instrument and reagent lifecycle

The cumulative impact of United States tariff actions in 2025 is exerting multidimensional pressure across the diagnostics value chain, prompting reassessment of sourcing, pricing, and localization strategies. Tariffs on key instrument components, reagent raw materials, and finished goods have amplified input cost volatility, intensifying procurement complexity for manufacturers and laboratories alike. In response, many firms are revisiting supplier networks to mitigate exposure to tariff-exposed geographies and are accelerating diversification of manufacturing footprints.

Beyond immediate cost implications, tariffs have affected capital equipment purchasing behavior. Healthcare organizations evaluating instrumentation purchases are factoring in extended total cost considerations, including potential import duties, logistical lead times, and maintenance parts availability. This has increased interest in domestically produced instruments or devices whose critical subcomponents originate in tariff-neutral jurisdictions, as well as in service contracts that include parts and reagent predictability to offset tariff-driven price fluctuations.

Strategically, tariffs have propelled a renewed focus on supply chain resilience and vertical integration. Companies are exploring onshoring of critical reagent production and localized assembly to stabilize delivery timelines and maintain competitive positioning. At the same time, regional regulatory and trade policy responses have introduced administrative complexity, with manufacturers required to manage differing compliance pathways and documentation to qualify for tariff exemptions or preferential treatment.

Taken together, the tariff environment in 2025 has shifted decision-making from short-term procurement arbitrage toward longer-term supply chain redesigns, supplier partnerships, and product strategies that emphasize modularity, local support, and predictable lifecycle economics.

Unpacking multidimensional segmentation across product, technology, end-user, application, test type, and sample type to reveal targeted commercialization imperatives and clinical priorities

A granular segmentation approach reveals differentiated requirements, adoption patterns, and commercialization pathways across product types, technologies, end users, applications, test types, and sample types. By product type, the landscape includes instruments-such as chemistry analyzers, immunoassay analyzers, and PCR instruments-alongside reagents and kits that span clinical chemistry reagents, immunoassay reagents, and molecular diagnostics reagents, and finally software and services comprised of data management platforms and maintenance services. Each product class demands distinct go-to-market models: instruments require capital sales, reagents depend on recurring consumption and supply chain optimization, and software and services center on integration and lifecycle revenue.

Technology segmentation highlights the diversity of underlying modalities, including clinical chemistry platforms that rely on electrochemical or photometric detection, immunoassay systems utilizing CLIA, ELISA, or FIA formats, microbiology approaches that range from culture-based methods to molecular assays, and molecular diagnostic techniques that include isothermal amplification, PCR-based workflows, and sequencing-based solutions. Technology choices influence assay turnaround time, sensitivity, infrastructure requirements, and laboratory staffing models, which in turn shape adoption across different clinical settings.

End-user segmentation spans diagnostic laboratories-both hospital laboratories and reference laboratories-hospitals and clinics that include secondary care hospitals and tertiary care centers, point-of-care locations, and research institutes. Adoption dynamics vary by end user, with high-throughput labs prioritizing automation and throughput, hospitals emphasizing integrated workflows and point-of-care responsiveness, and research institutes focusing on flexibility and novel assay adoption. Application-level differentiation includes autoimmune disease testing across celiac, lupus, and rheumatoid arthritis; cardiology assays such as cardiac markers and lipid panels; infectious disease testing for COVID-19, hepatitis, HIV, and tuberculosis; neurology diagnostics for Alzheimer's and Parkinson's disease; and oncology covering hematological and solid tumor testing, each with unique clinical evidence and regulatory pathways.

Test type distinctions-qualitative, quantitative, and semi-quantitative-combined with sample type considerations like blood, saliva, tissue, and urine, further influence assay design, regulatory classification, and user training requirements. This multifaceted segmentation underscores the necessity for tailored commercial strategies that align product development, regulatory planning, reimbursement engagement, and customer support with the specific demands of each segment.

Examining how regional market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific are influencing adoption, manufacturing strategies, and market access paths

Regional dynamics are shaping demand, innovation hubs, and investment patterns in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and advanced reimbursement frameworks continue to drive demand for integrated automation, molecular platforms, and data management solutions, while large hospital systems and reference laboratories push for scalable workflows and validated digital integrations. Strategic partnerships and localized service offerings are increasingly important to meet customer expectations for rapid installation, certified maintenance, and reagent continuity.

In the Europe, Middle East & Africa region, heterogeneous regulatory requirements and diverse healthcare financing models create both complexity and opportunity. The region's fragmented market structure rewards manufacturers who can navigate varied conformity assessment pathways, demonstrate clinical utility across multiple health systems, and offer flexible commercial models. Moreover, investment in public health infrastructure and infectious disease surveillance is prompting demand for both decentralized testing and robust laboratory reference capabilities.

Asia-Pacific presents a mosaic of mature and emerging markets where rapid adoption of molecular diagnostics, strong interest in point-of-care modalities, and substantial local manufacturing capacity are driving competitive intensity. Regional supply chain ecosystems, including component suppliers and reagent manufacturers, are enabling faster product localization, while differing clinical practice patterns and regulatory priorities require tailored evidence generation and market access approaches. Across all regions, sustainability considerations, workforce availability, and digital infrastructure will continue to influence deployment timelines and customer expectations.

Identifying how manufacturers, software vendors, and service providers are aligning portfolios, partnerships, and supply chains to secure competitive advantage in diagnostics

Leading industry players are pursuing a mix of platform consolidation, strategic partnerships, and service-centric models to capture expanding diagnostic opportunities. Manufacturers are investing in modular instrument architectures that support a broad assay menu while reducing time to market for new tests. Complementary investments in reagent stability, standardized consumable interfaces, and remote diagnostics capabilities are enhancing customer retention through improved uptime and total cost clarity.

Software and data management providers are emerging as pivotal collaborators, offering interoperability layers, cloud analytics, and decision-support tools that increase the clinical utility of laboratory outputs. These vendors are also engaging in co-development arrangements with instrument manufacturers to deliver turnkey solutions that simplify procurement and integration for healthcare providers. At the same time, service organizations are expanding maintenance, training, and reagent lifecycle programs to align commercial incentives with laboratory performance metrics.

Competitive differentiation is further influenced by strategic M&A activity and alliance formation aimed at closing gaps in assay portfolios, geographic presence, and digital capabilities. Companies that can demonstrate credible evidence packages, efficient regulatory pathways, and robust post-market surveillance are better positioned to secure long-term contracts with health systems and large reference laboratories. Supply chain excellence-including diversified sourcing, localized manufacturing, and responsive logistics-remains a critical determinant of commercial resilience and customer trust.

Actionable strategic priorities for industry leaders to align product architecture, data integration, evidence generation, and resilient supply chains to accelerate adoption

Industry leaders should prioritize an integrated approach that aligns product development, supply chain resilience, evidence generation, and go-to-market strategies to succeed in the next-generation diagnostics era. First, invest in modular instrument designs and open consumable systems that allow rapid assay expansion and reduce dependence on single-source components, thereby enabling faster response to clinical needs and tariff-related supply disruptions. This architectural flexibility will also facilitate integration with diverse software ecosystems and support hybrid deployment models across centralized and decentralized settings.

Second, strengthen data strategies by embedding interoperable data management capabilities into core offerings. This involves adopting industry data standards, ensuring robust cybersecurity, and developing analytics that translate laboratory outputs into actionable clinical insights. Demonstrating how data integration improves clinical pathways and operational efficiency will be essential for payer and provider adoption.

Third, develop evidence generation roadmaps that extend beyond analytical validation to include real-world performance, health economic assessments, and outcomes studies that support reimbursement and clinical guideline inclusion. Collaborate with key opinion leaders, clinical networks, and reference laboratories to generate reproducible multi-center data that aligns with regulatory and payer expectations.

Finally, proactively redesign supply chain and commercial models to mitigate tariff exposure, including nearshoring critical manufacturing, diversifying suppliers, and offering flexible commercial terms such as reagent-as-a-service or bundled maintenance agreements. Prioritize customer-centric service frameworks that emphasize uptime, training, and local technical support to build durable customer relationships and unlock long-term adoption.

Describing the transparent, interview-led, and evidence-triangulated research methodology underpinning the analysis to ensure reproducibility and strategic relevance

This research synthesis integrates a multi-source, evidence-based methodology designed to provide a robust and transparent foundation for strategic decision-making. Primary inputs include structured interviews with clinical laboratory directors, hospital procurement leaders, diagnostic R&D heads, and payers to capture first-hand perspectives on technology requirements, adoption barriers, and reimbursement priorities. These qualitative insights are triangulated with secondary sources such as regulatory filings, peer-reviewed literature, clinical guidelines, and industry announcements to validate technological trends and commercial movements.

Analytical approaches employ cross-segmentation mapping to assess how product types, technologies, end users, applications, test types, and sample matrices interact to influence adoption pathways and commercialization tactics. The methodology prioritizes reproducibility by documenting data provenance, interview protocols, and analytic assumptions, while sensitivity analyses are applied to scenario testing related to supply chain disruptions and policy changes.

Ethical considerations and data governance are integral to the research approach, ensuring that patient-level data used in secondary analysis are de-identified and that proprietary information obtained through interviews is anonymized unless explicit permission for attribution was provided. The resulting synthesis aims to deliver actionable insights that are defensible, transparent, and aligned with stakeholder realities across clinical, regulatory, and commercial domains.

Concluding synthesis on how technological integration, evidence strategies, and supply chain resilience will determine future competitive advantage in diagnostics

The trajectory of in vitro diagnostics is being reshaped by a convergence of technological innovation, evolving care delivery models, and shifting policy dynamics. Organizations that successfully navigate this landscape will be those that integrate modular product design, robust data strategies, and resilient supply chains while investing in the real-world evidence necessary to satisfy regulatory and reimbursement stakeholders. The interplay of instrumentation, reagents, and software continues to create opportunities for bundled offerings that simplify procurement and enhance clinical utility.

Regional differentiation and tariff-related supply chain considerations add layers of commercial complexity, but they also create openings for manufacturers that can localize production, offer service-centric commercial models, and demonstrate clear clinical and economic value. End users across diagnostic laboratories, hospitals and clinics, point-of-care settings, and research institutes will seek partners who can deliver predictable performance, seamless integration, and accountable service models.

In conclusion, the next wave of competitive advantage in diagnostics will be earned by organizations that translate technical capability into deployable solutions aligned with clinical workflows, payer requirements, and operational realities. Strategic investments in modular platforms, interoperable software, localized manufacturing, and evidence generation will position stakeholders to meet emerging clinical demands and capture sustained relevance in the diagnostic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and machine learning algorithms to improve sensitivity and specificity of point-of-care IVD diagnostics
  • 5.2. Development of multiplexed microfluidic platforms enabling simultaneous detection of multiple biomarkers in a single patient sample
  • 5.3. Adoption of digital health connectivity in IVD devices for real-time remote monitoring and data analytics integration
  • 5.4. Advancement of CRISPR-based gene editing techniques for ultrafast highly specific detection of pathogenic nucleic acids in clinical samples
  • 5.5. Rising use of novel nanomaterials such as quantum dots and gold nanoparticles for signal amplification in next-generation immunoassays
  • 5.6. Expansion of decentralized testing models leveraging smartphone-based sensors for at-home infectious disease screening
  • 5.7. Growth of personalized medicine initiatives driving demand for companion diagnostic assays tailored to targeted therapies
  • 5.8. Regulatory shifts emphasizing stringent validation standards and accelerated approval pathways for innovative IVD technologies
  • 5.9. Increasing focus on sustainable and disposable IVD cartridge designs to minimize biohazard waste and environmental footprint

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation IVD Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Chemistry Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. PCR Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Clinical Chemistry Reagents
    • 8.2.2. Immunoassay Reagents
    • 8.2.3. Molecular Diagnostics Reagents
  • 8.3. Software & Services
    • 8.3.1. Data Management Software
    • 8.3.2. Maintenance Services

9. Next-Generation IVD Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Electrochemical
    • 9.1.2. Photometric
  • 9.2. Immunoassay
    • 9.2.1. Clia
    • 9.2.2. Elisa
    • 9.2.3. Fia
  • 9.3. Microbiology
    • 9.3.1. Culture Based
    • 9.3.2. Molecular
  • 9.4. Molecular Diagnostic
    • 9.4.1. Isothermal Amplification
    • 9.4.2. PCR Based
    • 9.4.3. Sequencing Based

10. Next-Generation IVD Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital Laboratories
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals & Clinics
    • 10.2.1. Secondary Care Hospitals
    • 10.2.2. Tertiary Care Centers
  • 10.3. Point Of Care
  • 10.4. Research Institutes

11. Next-Generation IVD Market, by Application

  • 11.1. Autoimmune Diseases
    • 11.1.1. Celiac
    • 11.1.2. Lupus
    • 11.1.3. Rheumatoid Arthritis
  • 11.2. Cardiology
    • 11.2.1. Cardiac Markers
    • 11.2.2. Lipids
  • 11.3. Infectious Diseases
    • 11.3.1. Covid-19
    • 11.3.2. Hepatitis
    • 11.3.3. Hiv
    • 11.3.4. Tuberculosis
  • 11.4. Neurology
    • 11.4.1. Alzheimer's Disease
    • 11.4.2. Parkinson's Disease
  • 11.5. Oncology
    • 11.5.1. Hematological
    • 11.5.2. Solid Tumor

12. Next-Generation IVD Market, by Test Type

  • 12.1. Qualitative
  • 12.2. Quantitative
  • 12.3. Semi Quantitative

13. Next-Generation IVD Market, by Sample Type

  • 13.1. Blood
  • 13.2. Saliva
  • 13.3. Tissue
  • 13.4. Urine

14. Next-Generation IVD Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Next-Generation IVD Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Next-Generation IVD Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche Ltd.
    • 17.3.2. Abbott Laboratories
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Danaher Corporation
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. bioMerieux SA
    • 17.3.8. Sysmex Corporation
    • 17.3.9. QIAGEN N.V.
    • 17.3.10. Mindray Medical International Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NEXT-GENERATION IVD MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEXT-GENERATION IVD MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION IVD MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)

TA